Salute e Benessere

Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in…

"Alzheimer's disease is one of the world's most urgent healthcare challenges. Advances in early diagnosis, combined with treatments that enable earlier intervention, hold the potential to transform how we approach Alzheimer's, as well as other forms of dementia," ATx founder Dr. Hakon Hakonarson said. "Through our clinical trials targeting both rare and common forms of dementia, we are pushing the science forward with the goal of not only delaying progression, but ultimately…
PR Newswire
03/11/2025

Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

Vivoryon Therapeutics N.V. to Present at Upcoming ConferencesHalle (Saale) / Munich, Germany, November 3 , 2025- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November: American Society of...
Nasdaq GlobeNewswire
03/11/2025

IBA integrates Artificial Intelligence Quality Assurance into dosimetry…

Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance.Founded in 2018 by Dr...
Nasdaq GlobeNewswire
03/11/2025

Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction…

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwideIf approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity 1 These...
Nasdaq GlobeNewswire
03/11/2025

Alvotech Provides Update on the Status of U.S. Biologics License Application for…

REYKJAVIK, ICELAND (November 2, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab).The CRL noted that certain...
Nasdaq GlobeNewswire
02/11/2025

Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the…

COPENHAGEN, Denmark, November 1, 2025– Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and Response Authority (HERA) framework agreement, announced yesterday, and the Public Preparedness business.The initial order for 750,000 doses of MVA-BN smallpox/mpox vaccine that was announced yesterday will be delivered in 2026 and is the result of a new joint procurement contract by the European Commission, through the HERA. This represents...
Nasdaq GlobeNewswire
01/11/2025

Cellectis to Report Third Quarter Financial Results on November 7, 2025

The press release will be available in the Investors section of Cellectis’ website:https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions [email protected] CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic...
Nasdaq GlobeNewswire
31/10/2025

Teva to Present at UBS Global Healthcare Conference and Jefferies London…

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows: UBS Global Healthcare Conference Monday, November 10, 2025, at 8:45 A.M. Eastern Time (ET)Jefferies London Healthcare Conference Tuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET) To access a live webcast of the presentation, visit Teva’s Investor Relations website...
Nasdaq GlobeNewswire
31/10/2025

Fagron’s share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 27 October 2025 through 31 October 2025, Fagron purchased 46,000 of its owns shares at an average price of €20.5831 per share corresponding to a total amount of €946,821.80. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
31/10/2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, October 31, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% of the shares and voting rights in Bavarian Nordic A/S as of October 27, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
31/10/2025

Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the initiation of a new research and development program leveraging nanotechnology to enhance the effectiveness of phytochemical constituents used in its dietary supplement formulas.This new initiative builds upon the proprietary know-how developed during the creation of CCX Hydrogel, a breakthrough platform for optimised bioactive...
Nasdaq GlobeNewswire
31/10/2025

Disposable Endoscopes Market worth $2.67 billion by 2030 with 22.9% CAGR |…

Browse in-depth TOC on "Disposable Endoscopes Market" Browse in-depth TOC on "Disposable Endoscopes Market" 250 - Tables 60 - Figures 350 - Pages By type,the disposable endoscopes market is segmented into urology endoscopes, bronchoscopes, cystoscopes, laryngoscopes, GI endoscopes, arthroscopes, and other disposable endoscopes. Among these, the urology endoscopes segment held the largest market share in 2024, due to the rising prevalence of chronic kidney and ureteral...
PR Newswire
31/10/2025

Pet Perfume Market to Reach $2.7 billion, Globally, by 2034 at 6.7% CAGR: Allied…

Expanding product visibility through targeted marketing campaigns, celebrity associations with grooming product lines, and strong influence from pet-focused social media content have significantly raised awareness around pet perfume. In addition, the inclusion of pet perfume in grooming service bundles at parlors and spas has normalized regular usage. Manufacturers continue to introduce multipurpose products combining odor control with soothing or insect-repelling ingredients to address specific…
PR Newswire
31/10/2025

Bavarian Nordic shareholders are reminded of expiry of the offer period…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, 31 October, 2025– Reference is made to the company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (no. 33/2025) regarding the all-cash voluntary recommended public takeover offer to...
Nasdaq GlobeNewswire
31/10/2025

Correction: Evaxion to announce business update and third quarter 2025 financial…

Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Thursday November 6, 2025, before opening of the Nasdaq CM.Evaxion’s Executive Management will host a…
Nasdaq GlobeNewswire
31/10/2025

Elevaris Medical Devices Names New Chief Engineering and Operations Officer

"Sal brings vast global experience and is incredibly pedigreed in execution, operational excellence, and continuous improvement," said Richard Zrebiec, CEO of Elevaris Medical Devices. "We're excited about the discipline, energy, and vision he brings as we continue to strengthen our engineering and manufacturing capabilities to catapult growth and deliver exceptional value to our customers." "Sal brings vast global experience and is incredibly pedigreed in execution…
PR Newswire
31/10/2025

Evaxion to announce business update and third quarter 2025 financial results on…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Friday October 31, 2025, before opening of the Nasdaq CM.Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged...
Nasdaq GlobeNewswire
31/10/2025

Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI…

CPHI Frankfurt not only a platform for showcasing products and services, but also an important bridge for industry information sharing and resource integration. To this end, our company team actively visited competitor booths, scheduled meetings with clients, and exchanged information with industry partners on global pharmaceutical industry trends and overseas market policy dynamics. This accumulated valuable experience for optimizing our company's subsequent overseas expansion strategy, while…
PR Newswire
31/10/2025

Global Toothpaste Market Moves Toward Herbal and Online Momentum, says Mordor…

Consumers are increasingly choosing toothpaste made with natural and herbal ingredients, reflecting a growing preference for transparency and health-focused products. This shift is pushing brands to blend traditional remedies with modern science to enhance effectiveness. At the same time, demand for sensitivity-relief toothpaste is rising, driven by aging populations and awareness of oral health. Brands are also ramping up digital marketing through influencers and social media to reach younger…
PR Newswire
31/10/2025

Bavarian Nordic Awarded New Procurement Framework Contract by the European…

New and larger framework contract with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) replaces previous agreement and provides for up to 8 million doses of smallpox/mpox vaccine over the next four years.Additional countries have joined the agreement, now providing access to the vaccine for 20 EU member states and other European countries.COPENHAGEN, Denmark, October 31, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today the award of a joint...
Nasdaq GlobeNewswire
31/10/2025

Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate…

Mads Kjolby, Co-Founder and Chief Medical Officer at Vesper Bio, said: "Progranulin is vital for maintaining neuronal health. However, progranulin levels in asymptomatic people with GRN mutations are typically half that of people without such mutations. Based on these topline Phase Ib/IIa data, we believe VES001 has the potential to normalise progranulin levels not only in asymptomatic individuals with GRN mutations, but in symptomatic people too, without affecting other sortilin functions…
PR Newswire
31/10/2025

Implantica publishes Interim Report January - September 2025 (Q3)

Significant events in the third quarter of 2025 Significant events in the third quarter of 2025 Significant events after the end of the period Financial summary third quarter 2025 First nine months Telephone conference Implantica will hold a teleconference on31 October 2025at 15:00 (CET) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast...
PR Newswire
31/10/2025

DXS International plc ((AQSE: DXSP) - Final Results

DXS INTERNATIONAL PLC(AQSE: DXSP)ANNUAL RESULTSfor the year ended 30 April 2025The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2025. Financial highlights:Revenue increased by 5% to £3,469,917 (2024: £3,308,359). Core recurring revenue model remains resilient.Available cash at...
Nasdaq GlobeNewswire
31/10/2025

Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's…

"We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to provide innovative and competitive ADC solutions," said Pei-Jiun Chen, CEO and President of Mycenax. "This collaboration further enhances our technical capabilities and reinforces our commitment to advancing next-generation ADC therapeutics." "We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to…
PR Newswire
31/10/2025
Altri  Comunicati